non-small-cell_lung_cancer

Non-Small-cell lung cancer

Non small cell lung cancer (NSCLC) is any type of epithelial lung cancer other than Small-cell lung cancer (SCLC).

Includes: adenocarcinoma (the most common NSCLC), large cell, squamous cell, bronchoalveolar.

Lung cancer continues to be a leading cause of cancer-related death worldwide, with non-Small-cell lung cancer (NSCLC) accounting for more than 80% of lung cancer cases.

Lung cancer is the leading cause of cancer mortality worldwide, accounting for 1.38 million annual deaths, representing 18.2% of total deaths from cancer 1).

Non-Small-cell lung cancer (NSCLC) account for more than 80% of lung cancer cases.

Among those, approximately 7.4% of non-Small-cell lung cancer (NSCLC) patients will have brain metastases (BM) at presentation 2) , and between 20–40% of Non-Small-cell lung cancer (NSCLC) patients will develop intracranial metastases 3) 4).

see Non-Small-cell lung cancer classification.

Non-Small-cell lung cancer Diagnosis.

see Non-Small-cell lung cancer intracranial metastases.

Leptomeningeal metastasis (LM) is a fatal complication of advanced non-small-cell lung cancer (NSCLC).

Between 20–40% of Non-Small-cell lung cancer (NSCLC) patients will develop intracranial metastases 5) 6).

The concept of “oligometastasis” has emerged as a basis on which to identify patients with stage IV Non-Small-cell lung cancer (NSCLC) who might be most amenable to curative treatment. Limited data have been available regarding the survival of patients with node-negative oligometastatic NSCLC.

see Non-Small-cell lung cancer treatment.

see Non-Small cell lung cancer outcome.

Non-Small-cell lung cancer case series.


1)
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):134. PubMed PMID: 21296855.
2)
Schuette W. Treatment of brain metastases from lung cancer: chemotherapy. Lung Cancer. 2004 Aug;45 Suppl 2:S253-7. Review. PubMed PMID: 15552807.
3) , 5)
Brower JV, Robins HI. Erlotinib for the treatment of brain metastases in non-Small-cell lung cancer. Expert Opin Pharmacother. 2016;17(7):1013-21. doi: 10.1517/14656566.2016.1165206. Epub 2016 Mar 30. Review. PubMed PMID: 26967582.
4) , 6)
Zhao J, Chen M, Zhong W, Zhang L, Li L, Xiao Y, Nie L, Hu P, Wang M. Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma. Clin Lung Cancer. 2013 Mar;14(2):188-93. doi: 10.1016/j.cllc.2012.06.004. Epub 2012 Jul 28. PubMed PMID: 22846582.
  • non-small-cell_lung_cancer.txt
  • Last modified: 2021/06/21 12:17
  • by administrador